PCV81 Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective
No Thumbnail Available
Date
2017-10-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Value in Health
Abstract
Apixaban, dabigatran, and rivaroxaban are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF). Although warfarin remains the standard of care in Kazakhstan.The objective of this study was to evaluate the cost-effectiveness of apixaban against other NOACs and warfarin from the considering costs and savings for public payers perspective in Kazakhstan
Description
Keywords
Citation
A Kostyuk, A Almadiyeva, T Nurgozhin, PCV81 - Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective, In Value in Health, Volume 20, Issue 9, 2017, Page A615